DR REDDYS LABORATORIES LTD(RDY)— Stock Profile, AI Score & Financials

Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2025-03-31.

DR REDDYS LABORATORIES LTD (RDY) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RDY at 47.6/100 on a 32-signal composite quality model, placing it at rank #1,768 of 2,961 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (FY 2025), DR REDDYS LABORATORIES LTD reports quarterly revenue of $3.8B, net income of $671.0M. Top institutional holders of RDY by reported 13-F value include Robeco Institutional Asset Management B.V., MORGAN STANLEY, BlackRock, based on the most recent SEC filings. RDY trades on the NYSE exchange and files with the SEC under CIK 1135951. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RDY daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for DR REDDYS LABORATORIES LTD directly from SEC EDGAR.